EGFR and non-small cell lung carcinoma: However, it is particularly relevant for populations who are PD-L1 negative, have contraindications to immunotherapy, or are unable to afford costly treatments—especially given the current limited evidence indicating that the benefits of consolidation therapy with immunotherapy for patients with unresectable stage III EGFR-mutated NSCLC remain uncertain (16).